Arcturus Therapeutics is developing portfolio of mRNA therapeutics for treatment of diseases with unmet medical needs. Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of mRNA medicines.
May 21, 2020
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
May 8, 2020
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
May 7, 2020
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update